ABSTRACT
Some research suggests that GI symptoms seen in children with ASD may relate to behavior problems. The objective of this pilot study was to assess the effect of the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet on GI and behavioral problems in children with ASD. At follow-up, the low FODMAP diet group had significant relief in some GI problems compared with both baseline in the group and control group. At baseline and at follow-up, there were no significant differences in behavioral problems between the low FODMAP diet group and the control group. Randomized controlled studies including larger sample sizes are needed to confirm the effects of low FODMAP diets in children with autism who have gastrointestinal problems.
Subject(s)
Autism Spectrum Disorder/diet therapy , Child Behavior Disorders/diet therapy , Eating/physiology , Energy Intake/physiology , Fermentation/physiology , Gastrointestinal Diseases/diet therapy , Adolescent , Autism Spectrum Disorder/physiopathology , Autism Spectrum Disorder/psychology , Child , Child Behavior Disorders/physiopathology , Child Behavior Disorders/psychology , Disaccharides/administration & dosage , Eating/psychology , Female , Gastrointestinal Diseases/physiopathology , Gastrointestinal Diseases/psychology , Humans , Male , Monosaccharides/administration & dosage , Oligosaccharides/administration & dosage , Pilot Projects , Polymers/administration & dosage , Treatment OutcomeABSTRACT
The Children's Interview for Psychiatric Syndromes-Parent Version (P-ChIPS) is a structured psychiatric interview designed to assess the presence of psychiatric disorders in children and adolescents. This study examined the reliability and validity of the P-ChIPS in 61 youngsters (6- to 17-years-old) with Autism Spectrum Disorders. Reliability analyses were conducted according to level of functioning and language level. Results indicated that interrater reliability values were largely in the good to excellent range. Concordance between the P-ChIPS and the Child and Adolescent Symptoms Inventory was fair for the majority of disorders. Percent overall agreement for most disorders was good, lending support to the validity of the P-ChIPS. The results of this study suggest that the P-ChIPS is appropriate for this population.
Subject(s)
Child Development Disorders, Pervasive/diagnosis , Interview, Psychological , Psychiatric Status Rating Scales , Adolescent , Child , Child Psychiatry , Female , Humans , Male , Parents , Psychometrics , Reproducibility of ResultsABSTRACT
The classification of autism spectrum disorders (ASDs) is a topic of debate among clinicians and researchers with many questioning the validity of the distinction among subtypes. This manuscript examines the validity of three ASD subtypes (Autism, Asperger's, and PDDNOS) by reviewing 22 studies published between 1994 and 2006. We reviewed studies that examined differences between the subtypes in terms of clinical and demographic characteristics, neuropsychological profiles, comorbidity, and prognosis. Results largely did not support differences between autism and Asperger's disorder based on current diagnostic criteria. Overall, the most salient group differences were noted when samples were categorized on IQ. Drawing definitive conclusions is difficult due to the inconsistent application of diagnostic criteria and circularity in methods.
Subject(s)
Autistic Disorder/classification , Asperger Syndrome/diagnosis , Asperger Syndrome/psychology , Autistic Disorder/diagnosis , Autistic Disorder/psychology , Child , Cognition Disorders/diagnosis , Cognition Disorders/epidemiology , Comorbidity , Diagnostic and Statistical Manual of Mental Disorders , Female , Humans , International Classification of Diseases , Male , Mental Disorders/epidemiology , Reproducibility of ResultsABSTRACT
BACKGROUND: This study is the first to evaluate the Social Communication Questionnaire (SCQ) and the Developmental Behaviour Checklist-Autism Screening Algorithm (DBC-ASA) in the same sample of school-aged children with intellectual disability (ID) with and without Pervasive Developmental Disorders (PDDs). METHOD: Parents of 49 children (36 with PDDs and 13 with ID) completed a survey that included a demographic form, a measure of adaptive behaviour (the SIB-R), the SCQ, and the DBC-ASA. RESULTS: According to established cut-offs, the SCQ's sensitivity was .92 and specificity was .62, and the DBC-ASA's sensitivity was .94 and specificity was .46. Six of the seven false positives on the DBC-ASA had DBC Total Problem Behaviour scores above the clinical cut-off. By contrast, all six true negatives had Total Problem Behaviour scores below the clinical cut-off. No such pattern was noted for the SCQ. CONCLUSION: While both instruments have good psychometric properties, the results of this study suggest that clinicians and researchers should exercise caution when utilising the DBC-ASA to screen for PDDs in individuals with significant behaviour problems, as this could decrease its diagnostic validity.
Subject(s)
Algorithms , Autistic Disorder/diagnosis , Intellectual Disability/psychology , Surveys and Questionnaires , Autistic Disorder/psychology , Child , Female , Humans , Male , Psychological Tests , Reproducibility of Results , Sensitivity and Specificity , Social BehaviorABSTRACT
BACKGROUND: Methylphenidate has been shown elsewhere to improve hyperactivity in about half of treated children who have pervasive developmental disorders (PDD) and significant hyperactive-inattentive symptoms. We present secondary analyses to better define the scope of effects of methylphenidate on symptoms that define attention-deficit/hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD), as well as the core autistic symptom domain of repetitive behavior. METHODS: Sixty-six children (mean age 7.5 y) with autistic disorder, Asperger's disorder, and PDD not otherwise specified, were randomized to varying sequences of placebo and three different doses of methylphenidate during a 4-week blinded, crossover study. Methylphenidate doses used approximated .125, .25, and .5 mg/kg per dose, twice daily, with an additional half-dose in the late afternoon. Outcome measures included the Swanson, Nolan, and Pelham Questionnaire revised for DSM-IV (ADHD and ODD scales) and the Children's Yale-Brown Obsessive Compulsive Scales for PDD. RESULTS: Methylphenidate was associated with significant improvement that was most evident at the .25- and .5-mg/kg doses. Hyperactivity and impulsivity improved more than inattention. There were not significant effects on ODD or stereotyped and repetitive behavior. CONCLUSIONS: Convergent evidence from different assessments and raters confirms methylphenidate's efficacy in relieving ADHD symptoms in some children with PDD. Optimal dose analyses suggested significant interindividual variability in dose response.
Subject(s)
Attention Deficit Disorder with Hyperactivity/drug therapy , Attention Deficit Disorder with Hyperactivity/etiology , Central Nervous System Stimulants/therapeutic use , Child Development Disorders, Pervasive/complications , Methylphenidate/therapeutic use , Adolescent , Child , Child, Preschool , Cross-Over Studies , Diagnostic and Statistical Manual of Mental Disorders , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Psychiatric Status Rating Scales , Surveys and QuestionnairesABSTRACT
OBJECTIVE: To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). METHOD: Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6 weeks each, separated by 1-week washout. Slopes for each condition were compared by paired t test. RESULTS: In 2004-2005, 12 boys and 4 girls (7 with autistic disorder, 1 Asperger's, 8 pervasive developmental disorder not otherwise specified) all completed at least 3 weeks of each condition. On the primary outcome, the Hyperactivity subscale of the Aberrant Behavior Checklist, ATX was superior to placebo (p =.043, effect size d = 0.90). It was also superior on a 0 to 3 rating of nine DSM-IV ADHD hyperactive/impulsive symptoms (p =.005, d = 1.27), but missed significance on nine inattentive symptoms (p =.053, d= 0.89). Nine subjects responded to ATX, four to placebo (25% improvement on the Hyperactivity subscale plus Clinical Global Impressions-Improvement of 1-2. One was rehospitalized for recurrent violence on ATX. Adverse events were otherwise tolerable, with no tendency to stereotypy. CONCLUSIONS: ATX appears safe and effective for treating hyperactivity in some children with autism spectrum disorders. The effect appears as large as in a multisite methylphenidate trial in the same population, with fewer intolerable side effects. Further study in autism spectrum disorders is indicated.
